Welcome and introduction William Tarnow-Mordi When printing handouts, please select ‘Notes Pages’ option in “Print what” menu in lower left area of Print.

Slides:



Advertisements
Similar presentations
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Advertisements

BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Medical Statistics Joan Morris Professor of Medical Statistics Goldsmiths Lecture 2014.
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
Reporting drugs and treatments Thomas Abraham. What we will learn today The difference between absolute and relative risk reduction A basic way to interpret.
Clinical trial The Way We Make Progress Against Disease Prof. Ashry Gad Mohamed Prof. of Epidemiology College of Medicine & KKUH.
Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
1 Improving Chronic Care Management David M. Cutler Presented at Alliance for Health Reform Novartis/NIHCM Briefing March 28, 2008.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Clinical Trial Designs An Overview. Identify: condition(s) of interest, intended population, planned treatment protocols Recruitment of volunteers: volunteers.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
How to Analyze Therapy in the Medical Literature (part 2)
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Compliance Original Study Design Randomised Surgical care Medical care.
4S: Scandinavian Simvastatin Survival Study
EBM --- Journal Reading Presenter :林禹君 Date : 2005/10/26.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention of Cardiovascular Mortality and.
Date of download: 6/2/2016 From: Quantitative Synthesis in Systematic Reviews Ann Intern Med. 1997;127(9): doi: /
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Volume 385, Issue 9985, Pages (June 2015)
Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials  Cholesterol.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.
Heart Disease in the Acute Hospital
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.
The IDEAL Study Reference
AIM HIGH Niacin plus Statin to prevent vascular events
Improving Chronic Care Management
دانشیار دانشکده دندانپزشکی دانشگاه علوم پزشکی شهید صدوقی یزد
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Baseline characteristics of HPS participants by prior diabetes
The Hypertension in the Very Elderly Trial (HYVET)
The results of the SHARP trial
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
European Heart Association Journal 2007 April
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials  Cholesterol.
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials 
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
LRC-CPPT and MRFIT Content Points:
Volume 385, Issue 9985, Pages (June 2015)
The following slides are from a Cardiology Scientific Update in which Dr. Gordon Moe reported and discussed an original presentation by Drs. Bjorn Dahlof,
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials  Cholesterol.
Volume 382, Issue 9894, Pages (August 2013)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
The results of the SHARP trial
Basic statistics.
Presentation transcript:

Welcome and introduction William Tarnow-Mordi When printing handouts, please select ‘Notes Pages’ option in “Print what” menu in lower left area of Print Screen, as shown in next slide. When viewing slideshow, please click ‘View’ in top toolbar and select ‘Notes Pages’ from drop down menu.

International Neonatal Immunotherapy Study (INIS)

Sir Richard Doll Controlled trials: the 1948 watershed BMJ 1998: 317: Sir Richard Doll Controlled trials: the 1948 watershed BMJ 1998: 317: “Early randomised trials (1940s) can properly be criticised on the grounds that they were often too small to have any chance of detecting moderate effects. “Small trials can be successful when the effect is large but this seldom occurs.“

“It was many years before randomisation was accepted as such a normal procedure.

“Only then (1980s) did it become possible to organise the groundbreaking international study of infarct survival (ISIS) trials for the treatment of myocardial infarction, which involved hundreds of centres and randomly allocated tens of thousands of patients, and thereby showed the value of moderate improvements in the treatment of common diseases.”

Impact of progressive, moderate benefits on deaths from myocardial infarction in 10 years ISIS-1 (n = 16,000) 13% Mortality in placebo group Mortality in best treatment arm ISIS-28% ISIS-47% more than threefold increase in sample size between ISIS-1 and ISIS-4

Number Needed to Treat for statins to avoid coronary heart disease or death For ~ every 50 hypertensive men aged 55 who take daily statins, one fewer will suffer a coronary event or death in the next 10 years.

Power calculations to detect large or moderate treatment effects with 90% power at 2p = 0.05 Adverse outcome in controls (C) Adverse outcome in treatment group (T) Absolute risk difference (C-T) Total sample needed (both groups) 30%20%10%824 20%15%5%2,502 25%21%4%4,748 30%26%4%5,392 15%13%2%~17,000

If premature newborns are to benefit from evidence as reliable as in cardiology, much larger numbers are needed –i.e. thousands, not hundreds

Thank you! With nearly 1900 babies recruited, INIS –is the largest MRC multi-centre neonatal trial –quadruples the number of patients in the meta- analysis of IVIG for neonatal sepsis –is a model for national and international collaboration in neonatal trials –participants are making an important academic and scientific contribution to neonatal medicine.